CCND1 Knockout HEK293 Cell Line

The choice depends on whether you are studying CCND1 (cyclin D1)'s role as the canonical G1 cyclin or modeling cyclin D1 amplification-driven cancers (especially mantle cell lymphoma) and CDK4/6 inhibitor pharmacology. The Knockout line is the standard tool for asking whether Cyclin D1 is required for these processes — CCND1/Cyclin D1 partners with CDK4 and CDK6 to phosphorylate RB1 at G1 transition, releasing E2F transcription factors; CCND1 is among the most clinically actionable oncogenes — t(11;14) translocation causing cyclin D1 overexpression is the defining feature of mantle cell lymphoma (MCL), and CCND1 amplification is common in breast, head and neck, esophageal cancers. Overexpression is useful for studying cyclin D1 amplification effects. For cancer biology research, the EDITGENE CCND1 Knockout in HEK293 is uniquely valuable — Cyclin D1 is the partner of CDK4/6 (the parallel CDK4 and CDK6 Knockouts in HEK293 are also available), and CCND1-CDK4/6 axis is the target of the FDA-approved breast cancer drugs palbociclib/ribociclib/abemaciclib. CCND2, CCND3 paralog expression analysis aids interpretation given partial functional overlap. Rescue with wild-type or T286A (GSK3β-resistant, stable) cyclin D1 enables cancer modeling. The knockout is a critical specificity tool for ⭐⭐⭐ palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Verzenio) (FDA-approved CDK4/6 inhibitors for HR+ breast cancer), and emerging cyclin D1 PROTACs/degraders.

Primary applications: • Cyclin D1-CDK4/6 activity: CDK4/6 kinase activity and phospho-RB1 analysis in CCND1-null cells. • Breast cancer biology: in heterologous breast cancer-relevant contexts, characterization of cyclin D1-driven proliferation. • MCL modeling: in MCL-relevant contexts, characterization of t(11;14) cyclin D1 overexpression effects. • CDK4/6 inhibitor specificity: paired analysis with parallel CDK4 and CDK6 Knockouts in HEK293 (also available) for systematic palbociclib/ribociclib/abemaciclib pharmacology studies. • Cyclin D1 degrader development: T286A stable rescue and cyclin D1 PROTAC validation. EDITGENE recommends this model as a critical specificity control for CDK4/6 inhibitor breast cancer drug development and emerging cyclin D1 degrader research.

Yes. CCND1 rescue experiments are well-established for breast cancer research: • Construct design: use a codon-modified CCND1 sequence with a small C-terminal tag (FLAG, HA). CCND1 has cyclin-box domain and C-terminal T286 GSK3β phosphorylation site — preserve all elements. • T286A stable rescue: T286A mutation in the GSK3β phosphorylation site prevents proteasomal degradation, generating stable cyclin D1 — useful for studying CCND1 amplification and MCL t(11;14) overexpression effects. • CDK4/6-binding-deficient rescue: cyclin-box mutations disrupt CDK4/6 partnership. • Functional readout: rescue should restore Cyclin D1-CDK4/6 kinase activity and palbociclib/ribociclib/abemaciclib sensitivity. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for CDK4/6 inhibitor research.